Blar i Department of Clinical Science på tidsskrift "International Immunopharmacology"

Viser treff 1-1 av 1

    • Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro 

      Førde, Jan-Lukas; Herfindal, Lars; Myhr, Kjell-Morten; Torkildsen, Øivind; Mollnes, Tom Eirik; Skrede, Silje (Journal article; Peer reviewed, 2023)
      The clinical and adverse effects of the therapeutic monoclonal antibodies (mAb) ocrelizumab, ofatumumab and rituximab in multiple sclerosis (MS) are presently subject to extensive study. While the two former are approved ...